As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to watch in 2025.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

China's National Medical Products Administration has granted expanded approval to MSD's GARDASIL for use in males aged nine to 26 years.

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Actuate Therapeutics has gained OMPD from the EMA for elraglusib aimed at treating pancreatic ductal adenocarcinoma (PDAC).

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.